文献速递急性肾损伤慢性肾脏病

肾脏损伤与修复生物标志物对造影相关急性肾损伤的预测:PRESERVE试验子研究

Kidney Biomarkers of Injury and Repair as Predictors of Contrast-Associated AKI: A Substudy of the PRESERVE Trial.
PubMed 文献 · Am J Kidney Dis · 2019-09-20

PRESERVE试验子研究分析了造影前血浆和尿液中的损伤与修复蛋白对90天主要不良肾脏事件(MAKE-D)和造影相关急性肾损伤(CA-AKI)的预测能力。结果显示,调整基线eGFR和尿白蛋白肌酐比后,4种血浆和3种尿液标志物与MAKE-D相关,仅血浆KIM-1与CA-AKI显著相关。使用血浆KIM-1或YKL-40的第50百分位数筛选患者可将所需样本量减少30%。

要点

  • 造影前血浆KIM-1、NGAL、UMOD、YKL-40和尿液NGAL、IL-18、YKL-40与MAKE-D相关。
  • 仅血浆KIM-1与CA-AKI独立相关。
  • 血浆KIM-1或YKL-40第50百分位数筛选可减少30%样本量。

核心结论

  • 造影前损伤和修复生物标志物可适度预测MAKE-D,并提高未来CA-AKI试验效率。

研究设计与样本

  • 纵向分析,纳入PRESERVE试验部分参与者,测量造影前1-2小时血浆和尿液生物标志物。
  • 血浆生物标志物在916名参与者中测量,尿液在797名参与者中测量。

主要发现

  • 调整尿白蛋白肌酐比和基线eGFR后,4种血浆(KIM-1、NGAL、UMOD、YKL-40)和3种尿液(NGAL、IL-18、YKL-40)标志物与MAKE-D相关。
  • 仅血浆KIM-1与CA-AKI显著相关。
  • 生物标志物对MAKE-D的区分能力中等。

关键数值与推荐

  • 使用造影前血浆KIM-1或YKL-40第50百分位数筛选患者,所需样本量减少30%(约2000名参与者)。

临床怎么用

  • 造影前血浆KIM-1或YKL-40水平可用于富集高风险患者,优化未来CA-AKI临床试验设计。

局限性

  • 预后富集评估未考虑试验成本变化、筛查时间和失访。
  • 大多数参与者为男性,限制普适性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: The PRESERVE trial used a 2 × 2 factorial design to compare intravenous saline solution with intravenous sodium bicarbonate solution and oral N-acetylcysteine with placebo for the prevention of 90-day major adverse kidney events and death (MAKE-D) and contrast-associated acute kidney injury (CA-AKI) among patients with chronic kidney disease undergoing angiography. In this ancillary study, we evaluated the predictive capacities of preangiography injury and repair proteins in urine and plasma for MAKE-D, CA-AKI, and their impact on trial design. STUDY DESIGN: Longitudinal analysis. SETTING & PARTICIPANTS: A subset of participants from the PRESERVE trial. EXPOSURES: Injury (KIM-1, NGAL, and IL-18) and repair (MCP-1, UMOD, and YKL-40) proteins in urine and plasma 1 to 2 hours preangiography. OUTCOMES: MAKE-D and CA-AKI. ANALYTICAL APPROACH: We analyzed the associations of preangiography biomarkers with MAKE-D and with CA-AKI. We evaluated whether the biomarker levels could enrich the MAKE-D event rate and improve future clinical trial efficiency through an online biomarker prognostic enrichment tool available at prognosticenrichment.com. RESULTS: We measured plasma biomarkers in 916 participants and urine biomarkers in 797 participants. After adjusting for urinary albumin-creatinine ratio and baseline estimated glomerular filtration rate, preangiography levels of 4 plasma (KIM-1, NGAL, UMOD, and YKL-40) and 3 urine (NGAL, IL-18, and YKL-40) biomarkers were associated with MAKE-D. Only plasma KIM-1 level was significantly associated with CA-AKI after adjustment. Biomarker levels provided modest discriminatory capacity for MAKE-D. Screening patients using the 50th percentile of preangiography plasma KIM-1 or YKL-40 levels would have reduced the required sample size by 30% (∼2,000 participants). LIMITATIONS: Evaluation of prognostic enrichment does not account for changing trial costs, time needed to screen patients, or loss to follow-up. Most participants were male, limiting the generalizability of our findings. CONCLUSIONS: Preangiography levels of injury and repair biomarkers modestly predict the development of MAKE-D and can be used to improve the efficiency of future CA-AKI trials.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Parikh CR, Liu C, Mor MK, et al. Kidney Biomarkers of Injury and Repair as Predictors of Contrast-Associated AKI: A Substudy of the PRESERVE Trial. Am J Kidney Dis. 2019. PMID: 31547939. doi:10.1053/j.ajkd.2019.06.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。